Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (UFT). Objective: Report UFT-induced severe hyperlipidemia. Method: A 71-year-old male patient with metastatic colorectal cancer receiving capecitabine treatment was hospitalized at the end of the eighth cycle with the complaint of fatigue. Capecitabine treatment was discontinued in the patient in whom severe hyperlipidemia was detected together with disease progression. Gemphibrozile 1200 mg/day was initiated; patient's triglyceride level and serum cholesterol decreased from 1768 to 149 mg/dL and from 497 to 99 mg/dL, respectively, five weeks later. The patient started to receive UFT chemotherapy and after the second cycle, he presented to our hospital again with the complaints of fatigue, headache, and yellow vision. The investigations revealed a serum triglyceride level of 4115 mg/dL and a cholesterol level of 734 mg/dL. Results: UFT chemotherapy was discontinued and lipopheresis was administered for three consecutive days, and gemphibrozile was initiated again at a dose of 1200 mg/day. The clinical presentation might be due to oral fluoropyrimidine. Three weeks later, serum cholesterol and triglyceride levels decreased to 106 and 403 mg/dL, respectively. Conclusion: This case is a unique case of hyperlipidemia secondary to UFT. Monitoring of lipid levels, when using Fluoropyrimidine, as well as hemograms, liver and renal functions would be appropriate.
Clinical report
Oral fluoropyrimidines are agents that have been shown to be effective in the treatment of metastatic rectal cancer [1, 2] . Uracil/tegafur (UFT ® ) is a dihydropyrimidine dehydrogenase inhibitor that consists of tegafur and uracil at a molar rate of 1:4 [1] . Capecitabine exerts its efficacy by transforming into 5-fluorouracil (5-FU) in the tumor cell [2] . Although they are well-tolerated agents, their most common side effects include palmar-plantar erythrodysesthesia (hand-foot syndrome), diarrhea, and stomatitis. In the literature, the incidence of grade 3-4 hypertriglyceridemia (5 to 10 fold of the normal limit or >10 fold increase) was reported at a rate of 0.1-1% [3] .
In this report, we discussed a case of metastatic rectal cancer with a severe increase detected in serum triglyceride and cholesterol levels with both capecitabine and UFT use.
Case report
The After four cycles of chemotherapy in the patient with grade I palmar-plantar erythrodysesthesia, partial remission was achieved. Oxaliplatin was discontinued and the dose of capecitabine was decreased (1000 mg/m 2 ) and the treatment was continued for another four cycles. In May 2007 (after eight cycles of treatment), the patient presented with complaints of grade III palmar-plantar erythrodysesthesia and fatigue. Laboratory investigations revealed severe hyperlipidemia (serum cholesterol, TG, HDL, and LDL were 497, 1768, 70, and 39 mg/dL, respectively). Potential risk factors including changes in dietary regimen, weight gain, alcohol use, uncontrolled diabetes and hypothyroidism were excluded. Treatment was discontinued, considering that acute hypertriglyceridemia was secondary to capecitabine treatment. Gemfibrozil 1200 mg/day was initiated together with a low fat diet.
After five weeks, serum lipid parameters regressed to normal limits and the patient was started on UFT (300 mg/m 2 /day, in two divided doses given on days 1-14 every three weeks) chemotherapy. After two cycles of chemotherapy, the patient presented again to our hospital with complaints of fatigue, lack of appetite, abdominal pain, headache, and yellow vision. Serum cholesterol and TG levels were 734 and 4115 mg/dL, respectively.
Risk factors that may result in hypertriglyceridemia were re-evaluated and no reason other than UFT could be detected. The patient whose treatment was discontinued underwent lipopheresis for three consecutive days. After lipopheresis, serum TG level was determined to be 1953 mg/dL. Gemfibrozil 1200 mg/day was initiated again and three weeks later, serum cholesterol and TG levels declined to 106 and 403 mg/dL, respectively. The patient followed up with response of stable disease was detected to have progression in June 2009 and FOLFIRI-cetuximab treatment was initiated. In May 2009, the patient's serum TG and cholesterol level was 128 mg/dL and 219 mg/dL, respectively.
In Table 1 are shown information regarding our patient and other five patients that were available in the literature.
Discussion
There is no reported case of hypertriglyceridemia secondary to UFT use in the literature, but there are 10 cases of hypertriglyceridemia secondary to capecitabine [3] [4] [5] [6] . Five of these cases were completely described, and the remaining was detected by monitoring serum lipid parameters of other patients upon incidental detection of hypertriglyceridemia in a trial investigation of the efficacy and side-effects of capecitabine [4] .
Information regarding six patients with previously published data as well as our patient is presented in Table 1 . Four patients were receiving capecitabine at a dose of 2500 mg/m 2 /day, and two started treatment at a dose of 2000 mg/m 2 /day. In two patients, capecitabine dose was decreased by 25% after the increase in serum TG levels and the treatment was continued at this dose. However, TG levels increased again in both patients despite the dose reduction. Treatment had to be interrupted in three patients due to the increase in TG levels. Although serum lipid levels became normal after five-week interruption of treatment, a reduction of approximately 1.5 fold of the normal was detected in the other two cases. Both patients were receiving antihyperlipidemic treatment. Only in the case with colorectal cancer, serum TG level increased by approximately nine folds after two cycles, and 20 mg/day atorvastatin was added to treatment, and the therapy was continued for further four cycles. The patient completed his treatment with a TG level that is approximately 1.5 fold higher than the normal without requirement for treatment interruption.
Considering all the cases in the literature, there is no other case detected to have hypertriglyceridemia with both capecitabine and UFT use. In the literature, the highest serum TG level detected to date was 3090 mg/dL (15.5 fold of the upper limit), but in our patient, the serum TG level was detected as 4115 mg/dL (27.4 fold of the upper limit) following two cycles of UFT.
Up to now, no hypertriglyceridemia secondary to 5-FU use have been reported. However, Stathopoulos et al. [7] detected a fall in TG levels only in rabbits while a decrease in serum cholesterol level was observed in human and animal subjects given 5-FU. This suggests that there may be a relation between 5-FU and the lipid metabolism. There are no cases of hypertriglyceridemia associated with UFT use in the literature.
The etiology of hypertriglyceridemia induced by oral fluoropyrimidines is unknown yet. Certainly, these agents (or their intermediate metabolites) might occur during transformation to 5-FU may be involved. However, considering its observation in only 0.1-1% of the patients, differences in drug metabolism and Another reason why hypertriglyceridemia secondary to oral fluoropyrimidines is serum lipid profile is not routinely monitored in these patients. Likewise, Koutras et al. [5] added regular lipid level monitoring to their study protocol upon incidental detection of high serum lipid levels in a patient, and TG levels were detected to be three to four fold higher than the normal in five of the 12 patients. Therefore, we believe that regular monitoring of lipid levels would be appropriate in patients who are using oral fluoropyrimidine.
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